Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.06 CHF | +1.04% | +0.12% | +18.48% |
22/05 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
22/05 | Sandoz Group Receives EU Approval for Cancer, Osteoporosis Biosimilars | MT |
Sales 2024 * | 1.03TCr 927.7Cr 86TCr | Sales 2025 * | 1.1TCr 987.59Cr 91TCr | Capitalization | 1.52TCr 1.37TCr 1,27200Cr |
---|---|---|---|---|---|
Net income 2024 * | 71Cr 64Cr 5.92TCr | Net income 2025 * | 97Cr 88Cr 8.12TCr | EV / Sales 2024 * | 1.78 x |
Net Debt 2024 * | 311.53Cr 280.81Cr 26TCr | Net Debt 2025 * | 273.17Cr 246.23Cr 23TCr | EV / Sales 2025 * | 1.64 x |
P/E ratio 2024 * |
21.8
x | P/E ratio 2025 * |
15.6
x | Employees | 22,633 |
Yield 2024 * |
1.79% | Yield 2025 * |
2.31% | Free-Float | 91.29% |
Latest transcript on Sandoz Group AG
1 day | +1.04% | ||
1 week | +0.12% | ||
1 month | +3.42% | ||
3 months | +14.70% | ||
6 months | +24.80% | ||
Current year | +18.48% |
Date | Price | Change | Volume |
---|---|---|---|
31/24/31 | 32.06 | +1.04% | 1,999,753 |
30/24/30 | 31.73 | +0.51% | 583,968 |
29/24/29 | 31.57 | -2.23% | 930,222 |
28/24/28 | 32.29 | -0.68% | 595,126 |
27/24/27 | 32.51 | +1.53% | 438,205 |
Delayed Quote Swiss Exchange, May 31, 2024 at 09:00 pm IST
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.48% | 1.52TCr | |
+15.91% | 4.2TCr | |
+22.40% | 2.23TCr | |
+16.12% | 1.4TCr | |
+45.12% | 1.21TCr | |
-9.58% | 679.6Cr | |
-0.05% | 678.76Cr | |
-8.87% | 572.55Cr | |
+14.18% | 549.33Cr | |
+4.00% | 462.48Cr |
- Stock Market
- Equities
- SDZ Stock